Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs PayPal Holdings, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while PayPal Holdings, Inc. trades at $46.75 (market cap $40.86B). The key difference: Alnylam Pharmaceuticals, Inc. and PayPal Holdings, Inc. are close in size by market cap, and PayPal Holdings, Inc. pays a 1.21% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PYPL | |
|---|---|---|
Market Cap | $39.89B | $40.86B |
Sector | Health | Financials |
52-Week High | $491.22 | $78.22 |
52-Week Low | $278.09 | $39.08 |
Enterprise Value | $38.15B | $40.93B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
PayPal (PYPL) trades at $46.32, up 2.21% today, with a bullish technical signal and strong fundamentals including a low P/E of 8.69 and robust net income margin of 15%. Recent earnings beat expectations in Q1 2026, and the company is targeting $1.5B in AI-driven savings to fuel growth. The stock is near resistance at $46, with support at $44.
PYPL presents a value opportunity with attractive valuation multiples and steady revenue growth, but faces competition and margin pressure. Analyst consensus is mixed with a $48.36 price target, indicating modest upside. Risks include execution challenges and macroeconomic headwinds, yet strong cash flow supports shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
